Dr. Joshua Sabari, Dr. Petros Grivas, and Dr. Chandler Park discuss new developments in perioperative therapy for muscle-invasive bladder cancer.
Dr. Petros Grivas
Advertisement
Dr. Petros Grivas is the clinical director of the Genitourinary Cancers Program and a professor in the Clinical Research Division at Fred Hutch Cancer Center, in Seattle; he also serves as a professor in the Division of Hematology and Oncology, at the University of Washington School of Medicine.
Articles by Dr. Petros Grivas
Experts highlight perioperative Padcev plus Keytruda in bladder cancer, showing potential practice-changing results from ESMO 2025 for patients.
Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas.
Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the JAVELIN Bladder 100 trial.
Dr. Petros Grivas discusses the importance of tailoring treatment decisions in bladder cancer based on data from three practice-changing phase 3 trials.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Breaking Down Advancements in Prostate Cancer Care
2
FDA Approves First Interchangeable Biosimilar to Perjeta in HER2+ Breast Cancer
3
When One Blood Draw Could Tell More: A Look at the Cancerguard Test
4
Kidney Cancer Disparities Persist Among American Indian and Alaskan Native Patients
5
